

Adrian Ray joins Nimbus Therapeutics as SVP of discovery biology

10 July 2018 | News

At Nimbus, Dr. Ray will leverage an increasingly diversified set of discovery and development capabilities and help to advance a growing number of pipeline programs centered around the interrelated targets affecting metabolic disease, oncology and immunology.



After 15 years at Gilead, Adrian Ray, Senior Director of Clinical Research, Gilead Sciences has moved over to Nimbus Therapeutics to become its senior vice president of discovery biology.

At Nimbus, Dr. Ray will leverage an increasingly diversified set of discovery and development capabilities and help to advance a growing number of pipeline programs centered around the interrelated targets affecting metabolic disease, oncology and immunology.

"Adrian is an outstanding addition to our already world-class team, who will strengthen our capabilities in discovery science rooted in cutting-edge biology and human genetics," said Don Nicholson, Ph.D., Chief Executive Officer at Nimbus. "Adrian is a capable leader in target discovery throughout the metabolic-oncology-immunology target space, and in the translation of these discoveries into effective clinical development strategies. We're thrilled to have him."

Dr. Ray holds a doctorate in pharmacology from Yale University and a bachelor's degree in molecular, cellular and developmental biology from University of California, Santa Cruz. He has authored over 100 publications and is listed as an inventor on 27 U.S.-granted patents.